Novartis will present data from studies across its neuroscience portfolio, including seven-year disability outcomes and safety data from the ALITHIOS open-label extension trial of Kesimpta® (ofatumumab) in people with relapsing multiple sclerosis (RMS), at the American Academy of Neurology (AAN) 2025 Annual Meeting in San Diego from April 5-9, 2025. Additional data on Kesimpta and pipeline assets including remibrutinib and iptacopan will also be highlighted.
Data to be presented at AAN include:
Abstract Title
Abstract Number/
Presentation Details
Kesimpta
Continuous Ofatumumab Treatment Up to 7 Years Shows a
Consistent Safety Profile and Delays Disability Progression
in People with Relapsing Multiple Sclerosis
P7.016
Monday,
April 7
5:00 – 6:00 PM PT
Long-Term Ofatumumab Treatment Over 6 Years Did Not
Increase the Risk of Serious Infections
P8.017
Tuesday,
April 8
8:00 – 9:00 AM PT
Longer-Term (up to 6 Years) Efficacy and Safety of
Ofatumumab in People with Non-highly Active MS Early
in the Disease Course
P11.003
Wednesday,
April 9
8:00 – 9:00 AM PT
Real-World Data on Ofatumumab as First-line Treatment in
Early RMS (AIOLOS Study)
P7.013
Monday,
April 7
5:00 – 6:00 PM PT
For full prescribing information, including approved indications and important safety information about marketed products, please visit https://www.novartis.com/about/products
